Mirimus was established in 2010 to harness the power of RNAi and genetic engineering technologies based on pioneering work by our founders in the labs of the world’s leading experts at Cold Spring Harbor Laboratory, Howard Hughes Medical Institute, and Harvard Medical School. Initially focused on using this technology to generate animal models of disease, Mirimus has since expanded the application of our unique expertise and insights into RNAi and genetic engineering across the R&D and clinical care continuum to include RNAi therapeutics, and advanced drug discovery and development technologies. Using proprietary RNA structures and screening techniques that stabilize RNAi constructs and improve their functionality by increasing potency and reducing off-target effects, we can preclinically evaluate the effects of drug therapy and even combination therapy both in vitro and in live animal models.